When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours?

Naykky Singh Ospina, Spyridoula Maraka, Victor Manuel Montori, Geoffrey B. Thompson, William Francis Young

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Patients with multiple endocrine neoplasia type 1 (MEN1) are commonly evaluated for clinical manifestations of this syndrome with the rationale that early diagnosis and adequate treatment will result in improved survival and quality of life. Thymic and bronchial carcinoid tumours are uncommon but important manifestations of MEN1. Current practice guidelines recommend evaluation with computed tomography or magnetic resonance imaging scan of the chest every 1-2 years to detect these neoplasms. However, the certainty that patients will be better off (increased survival or quality of life) as a result of this case detection strategy is based on evidence at moderate-high risk of bias that yields only imprecise results of indirect relevance to these patients. In order to improve the care that patients with MEN1 receive, co-ordinated efforts from different stakeholders are required so that large, prospective, multicentre studies evaluating patient important outcomes are carried out.

Original languageEnglish (US)
Pages (from-to)13-16
Number of pages4
JournalClinical Endocrinology
Volume84
Issue number1
DOIs
StatePublished - Jan 1 2016

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours?'. Together they form a unique fingerprint.

  • Cite this